| 1 |
34239043 | A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers. | 2021 Aug |
1 |
| 2 |
30021909 | Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. | 2018 Nov 1 |
1 |
| 3 |
30305055 | Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. | 2018 Oct 11 |
1 |
| 4 |
28415602 | ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. | 2017 May 30 |
2 |
| 5 |
25789974 | Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. | 2015 Mar 19 |
2 |
| 6 |
22219388 | Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. | 2012 Apr |
1 |
| 7 |
22357666 | Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. | 2012 May |
1 |
| 8 |
20571878 | Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. | 2011 Dec |
1 |
| 9 |
20855960 | Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. | 2010 Nov 1 |
5 |
| 10 |
19823038 | Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. | 2009 Nov |
4 |
| 11 |
18544666 | Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. | 2008 Sep |
2 |